ASND Ascendis Pharma AS

$194.30

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Ascendis Pharma AS

Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.

Website: https://ascendispharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1612042
Address
TUBORG BOULEVARD 12, HELLERUP, DK
Valuation
Market Cap
$9.92B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
14.55
Performance
EPS
$-7.38
Dividend Yield
—
Profit Margin
-104.00%
ROE
-818.00%
Technicals
50D MA
$149.99
200D MA
$137.16
52W High
$169.37
52W Low
$111.09
Fundamentals
Shares Outstanding
60M
Target Price
$215.77
Beta
0.54

ASND EPS Estimates vs Actual

● Estimated
● Actual

ASND News & Sentiment

Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Ascendis ( ASND ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 4:30 p.m. ETPresident and Chief Executive Officer - Jan Moller MikkelsenContinue reading ...
Jul 16, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts Believe Ascendis Pharma ( ASND ) Could Rally 29.83%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 29.8% in Ascendis Pharma (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Jul 14, 2025 • Benzinga NEUTRAL
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH ( Palopegteriparatide ) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life - Ascendis Pharma ( NASDAQ:ASND )
COPENHAGEN, Denmark, July 14, 2025 ( GLOBE NEWSWIRE ) -- Ascendis Pharma A/S ASND today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH ( palopegteriparatide ) continued to provide a durable response in adults with ...
Jun 09, 2025 • GlobeNewswire SOMEWHAT-BULLISH
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity ( AGV ) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks ...
May 12, 2025 • Benzinga NEUTRAL
New 4-Year Data Shows Sustained Response to TransCon® PTH ( Palopegteriparatide ) Therapy in Adults with Hypoparathyroidism - Ascendis Pharma ( NASDAQ:ASND )
COPENHAGEN, Denmark, May 12, 2025 ( GLOBE NEWSWIRE ) -- Ascendis Pharma A/S ASND today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH ( palopegteriparatide ) continued to provide a durable response in adults with ...
May 12, 2025 • GlobeNewswire NEUTRAL
New 4-Year Data Shows Sustained Response to TransCon® PTH ( Palopegteriparatide ) Therapy in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, May 12, 2025 ( GLOBE NEWSWIRE ) -- Ascendis Pharma A/S ( Nasdaq: ASND ) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH ( palopegteriparatide ) continued to provide a durable response in adults with ...
Sentiment Snapshot

Average Sentiment Score:

0.110
50 articles with scored sentiment

Overall Sentiment:

Neutral

ASND Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
-0.07 Surprise
  • Reported EPS: $-1.58
  • Estimate: $-1.51
  • Whisper: —
  • Surprise %: -5.0%
Feb 13, 2025
Dec 31, 2024 (Pre market)
0.29 Surprise
  • Reported EPS: $-0.64
  • Estimate: $-0.93
  • Whisper: —
  • Surprise %: 31.4%
Nov 05, 2024
Sep 30, 2024 (Post market)
0.17 Surprise
  • Reported EPS: $-1.72
  • Estimate: $-1.89
  • Whisper: —
  • Surprise %: 9.0%
Sep 03, 2024
Jun 30, 2024 (Post market)
-0.65 Surprise
  • Reported EPS: $-2.11
  • Estimate: $-1.46
  • Whisper: —
  • Surprise %: -44.5%
May 02, 2024
Mar 31, 2024 (Post market)
-0.8 Surprise
  • Reported EPS: $-2.30
  • Estimate: $-1.50
  • Whisper: —
  • Surprise %: -53.3%
Feb 07, 2024
Dec 31, 2023 (Post market)
0.49 Surprise
  • Reported EPS: $-1.54
  • Estimate: $-2.03
  • Whisper: —
  • Surprise %: 24.1%
Nov 07, 2023
Sep 30, 2023 (Post market)
-0.5 Surprise
  • Reported EPS: $-2.88
  • Estimate: $-2.38
  • Whisper: —
  • Surprise %: -21.0%
Sep 05, 2023
Jun 30, 2023 (Post market)
0.43 Surprise
  • Reported EPS: $-2.16
  • Estimate: $-2.59
  • Whisper: —
  • Surprise %: 16.6%
Apr 27, 2023
Mar 31, 2023 (Post market)
0.68 Surprise
  • Reported EPS: $-1.98
  • Estimate: $-2.66
  • Whisper: —
  • Surprise %: 25.6%

Financials